PMN ProMIS Neurosciences: Forward P/S Multiple

Official company branding of ProMIS Neurosciences, Inc. (PMN)

The development of therapies for neurodegenerative pathologies is independent of macroeconomics, rendering the business non-cyclical for ProMIS Neurosciences (PMN). The expected P/S multiple visualizes these characteristics, with recorded as the baseline value. However, a high burn rate and competition in Alzheimer's treatment create financial instability. These risks are mitigated through long-term contracts with CDMO vendors, which guarantee the quality of the produced antibodies.

PMN (ProMIS Neurosciences Inc.) Market Cap to Future Revenue Ratio history from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for promisneurosciences.com (PMN)

- market price and analyst price targets:
Price Chart ProMIS Neurosciences, Inc.|PMN - Average Forecast Price
- company stock capitalization data:
Market Capitalization ProMIS Neurosciences, Inc.|PMN - Full Takeover Company Value
- issuer book value statistics:
Accounting Value per Share ProMIS Neurosciences|PMN - Total Stockholders' Equity|Market Value to Book Value Ratio promisneurosciences.com|PMN - Total Asset Value of Company
- debt and liquidity details:
Debt to Equity ProMIS Neurosciences|PMN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ProMIS Neurosciences, Inc.|PMN - Company Cumulative Debt|Debt to Book Capitalization Ratio ProMIS Neurosciences, Inc.|PMN - Company Long-Term Liabilities|Company Short-Term Debts ProMIS Neurosciences|Quick Liquidity promisneurosciences.com
- net income and valuation multiples indicators:
PMN - Net Financial Result|Future Profit ProMIS Neurosciences|PMN - Company Value to Net Income|Future Price to Earnings ProMIS Neurosciences, Inc.|PMN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple ProMIS Neurosciences, Inc.|PMN - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months ProMIS Neurosciences|PMN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months promisneurosciences.com|PMN - Earnings per share increase in current year|Net earnings per share growth forecast for next year ProMIS Neurosciences
- revenue and sales details:
PMN - Company Total Revenue|Company Projected Revenue ProMIS Neurosciences, Inc.|PMN - Price-to-Revenue Coefficient|Forward P/S Multiple ProMIS Neurosciences, Inc.
Initial company analysis:PMN (ProMIS)
Original product of ProMIS Neurosciences, Inc.

To assess the resilience of ProMIS Neurosciences (PMN) amid a fierce battle with pharma behemoths for the Alzheimer's therapy market, monitoring the expected business value is critical. By analyzing the forward price-to-sales valuation trend, an investor can compare market capitalization with projected revenues, making it possible to identify cooling interest in the asset or the risk of a prolonged correction against the backdrop of competitors' successes.

Competitors of ProMIS Neurosciences (PMN)

Price-to-Projected Revenue Ratio Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. (CYTK) - Market Cap to Future Revenue Ratio|PTC Therapeutics Corp - Forward P/S Multiple|Projected Price to Revenue Scholar Rock Inc. (SRRK)|CNTA (Centessa Pharmaceuticals) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio dyne-tx.com (DYN)|Price-to-Projected Revenue Ratio Edgewise Therapeutics, Inc.|Rapport Therapeutics Inc - Future Price to Revenue|Price-to-Projected Revenue Ratio Alumis Corp (ALMS)|ZVRA (Zevra Corp) - Forward Price to Sales|Price-to-Projected Revenue Ratio Contineum Therapeutics, Inc. CTNM|larimartx.com (LRMR) - Market Cap to Future Revenue Ratio|CAPR - Price-to-Projected Revenue Ratio|Entrada Therapeutics Inc. (TRDA) - Forward Price-to-Revenue Multiple|PTHS: Forward P/S Multiple|MNOV - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Serina Therapeutics, Inc.|bioxceltherapeutics.com (BTAI) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple APUS (Apimeds Pharmaceuticals)|AEON (aeonbiopharma.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio NLS Pharmaceutics NLSP|BNOX: Market Cap to Projected Revenue|FSD Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio reatapharma.com